Nasonex Spray Nasal Dose. 50mcg 120dose
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Mometasone
Release form
Spray
Composition
Active ingredient: Mometasone (Mometasone) Active ingredient concentration (mg): 50 mcg
Pharmacological effect
GCS for local use. It has anti-inflammatory and anti-allergic effect when used in doses at which no systemic effects occur. It slows down the release of inflammatory mediators. It increases the production of lipomodulin, which is an inhibitor of phospholipase A, which causes a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of products of the metabolism of arachidonic acid - cyclic endoperoxides, prostaglandins. It warns the regional accumulation of neutrophils, which reduces inflammatory exudate and production of lymphokines, inhibits the migration of macrophages, leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of a chemotaxis substance (effect on late allergy reactions), inhibits the development of an immediate type allergic reaction (due to inhibition of arachidonic acid metabolite production and a decrease in inflammatory mediator release from mast cells). In studies with provocative tests with antigens applied to the mucous membrane The nasal cavity was shown to have a high anti-inflammatory activity of mometasone, both in the early and late stages of allergic reaktsii.Eto was confirmed reduction (compared to placebo) concentration of histamine and eosinophil activity and a decrease (compared to baseline), number of eosinophils, neutrophils and epithelial cell adhesion proteins.
Pharmacokinetics
Absorption When used intranasally, mometasone furoate has a systemic bioavailability of less than 1% (with a detection rate of 0.25 pg / ml). Momethasone is very poorly absorbed from the gastrointestinal tract. Metabolism and excretion through the liver. Excreted in urine and bile.
Indications
Seasonal and perennial allergic rhinitis in adults, adolescents and children from 2 years; acute sinusitis or exacerbation of chronic sinusitis in adults (includingelderly) and adolescents from 12 years of age - as an auxiliary therapeutic agent in the treatment with antibiotics; acute rhinosinusitis with mild and moderately severe symptoms without signs of severe bacterial infection in patients aged 12 years and older; prevention of moderate seasonal and allergic rhinitis in adults and adolescents from the age of 12 (recommended 2-4 weeks before the expected start of the dusting season); nasal polyposis, accompanied by a violation of nasal breathing and smell in adults (18 years).
Contraindications
The recent surgery or injury of the nose with damage to the nasal mucosa - until the wound heals (due to the inhibitory effect of the SCS on the healing processes); childhood and adolescence (with seasonal and year-round allergic rhinitis - up to 2 years, with acute sinusitis or exacerbation of chronic sinusitis - up to 12 years, with polyposis - up to 18 years) - due to the lack of relevant data; hypersensitivity to the components of the drug. The drug should be used with caution in case of tuberculosis infection (active or latent) of the respiratory tract, an untreated fungal, bacterial, systemic viral infection or infection caused by Herpes simplex with eye damage (as an exception, the drug may be prescribed the instructions of the doctor), the presence of untreated local infection with involvement in the process of the nasal mucosa.
Precautionary measures
Do not exceed the recommended dose. With caution, you should use the drug for tuberculosis infection (active or latent) of the respiratory tract, untreated fungal, bacterial, systemic viral infection or infection caused by Herpes simplex with eye damage (as an exception, the drug may be prescribed for these infections as directed physician), the presence of untreated local infection with involvement in the process of the nasal mucosa.
Use during pregnancy and lactation
Special, well-controlled studies of the safety of the use of the drug Nasonex during pregnancy have not been conducted. Like other GCS for intranasal use,Nasonex should be prescribed during pregnancy and during breastfeeding only if the expected benefit from its use justifies the potential risk to the fetus or infant. Infants whose mothers received GCS during pregnancy should be carefully examined to identify possible adrenal hypofunction.
Dosage and administration
The drug is used intranasally.
Side effects
Headache, nasal bleeding (i.e. obvious bleeding, as well as discharge of blood-stained mucus or blood clots), pharyngitis, burning sensation in the nose, irritation of the nasal mucosa, ulceration of the nasal mucosa, sneezing, bronchospasm, shortness of breath, anaphylaxis, angioedema, taste and smell.
Overdose
With prolonged use of GCS in high doses or with the simultaneous use of several GCS, hypothalamic-pituitary-adrenal system may be inhibited. The drug has a low systemic bioavailability (less than 1%, with a detection method sensitivity of 0.25 pg / ml), therefore it is unlikely that with an accidental or deliberate overdose any special measures will be required, in addition to observation, with the possible subsequent resumption of the drug in the recommended dose.
Interaction with other drugs
Combination therapy with loratadine was well tolerated by patients. However, no effect of the drug on the concentration of loratadine or its main metabolite in the blood plasma was noted. In these studies, mometasone furoate was not detected in the blood plasma (with a sensitivity of the method of determination of 50 pg / ml).
special instructions
As with any long-term treatment, patients using the Nasonex nasal spray for several months or longer should be examined periodically by a doctor for possible changes in the nasal mucosa. It is necessary to monitor patients receiving intranasal GCS for a long time. Perhaps the development of growth retardation in children. In case of detection of growth retardation in children, it is necessary to reduce the dose of intranasal GCS to the lowest, allowing to effectively control the symptoms. In addition, the patient should be referred to a pediatrician for consultation. If a local fungal infection of the nose or pharynx develops, it may be necessary to discontinue Nasonex nasal spray therapy and conduct special treatment.Prolonged irritation of the nasal and pharyngeal mucous membranes can also serve as a basis for discontinuing the nasonex nasal spray. When conducting placebo-controlled clinical trials in children, the Nasonex nasal spray was used at a daily dose of 100 mcg for a year, growth retardation in children not noted. With prolonged treatment with a Nasonex nasal spray, no signs of suppression of the hypothalamic-pituitary-adrenal system were observed. Patients who switch to treatment with Nasonex nasal spray after long-term treatment of systemic corticosteroids require special attention. Cancellation of GCS systemic action in these patients may lead to a lack of adrenal function, the subsequent restoration of which can take up to several months. If signs of adrenal insufficiency appear, systemic corticosteroids should be resumed and other necessary measures taken. With the use of intranasal corticosteroids, systemic side effects may develop, especially with prolonged use at high doses. The likelihood of these effects is significantly less than with the use of oral corticosteroids. Systemic side effects may vary both in individual patients, and depending on the used GCS. Potential systemic effects include Cushing's syndrome, characteristic signs of cushingoid, suppression of adrenal function, growth retardation in children and adolescents, cataracts, glaucoma, and more rarely a number of psychological or behavioral effects, including psychomotor hyperactivity, sleep disturbance, anxiety, depression, or aggression (especially children). During the transition from treatment of systemic corticosteroids to nasal spray treatment with Nasonex, some patients may experience initial symptoms of systemic corticosteroids withdrawal (for example, pain in the joint wah and / or muscles, feeling tired and depressed), despite the reduction in the severity of symptoms associated with damage to the nasal mucosa. Such patients need to be specifically convinced of the desirability of continuing treatment with Nasonex nasal spray. The transition from systemic to local corticosteroids can also reveal already existing, but masked, therapy of corticosteroids of systemic action, allergic diseases,such as allergic conjunctivitis and eczema. Patients who are treated with GCS have potentially reduced immune reactivity and should be warned about the increased risk of infection in case of contact with patients with certain infectious diseases (for example, chicken pox, measles), and the need medical consultation, if such contact occurred. If signs of severe bacterial infection appear (for example, fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area), immediate medical consultation is required. When using the Nasonex nasal spray for 12 months, there were no signs of mucosal atrophy the nose. In addition, mometasone furoate tended to contribute to the normalization of the histological pattern in the study of nasal mucosal biopsy specimens. The efficacy and safety of mometasone was not studied in the treatment of unilateral polyps, cystic fibrosis-associated polyps and polyps that completely cover the nasal cavity. Forms, especially ulcerated or bleeding, require additional medical examination. The effect on the ability to manage t nsportnymi means and work with mehanizmamiNet data on the effect of the drug Nasonex on the ability to drive a car or moving machinery.